Health insurance companies face market tension after President Trump’s negative remarks on the ACA. Companies like Centene, Oscar Health, and Elevance Health were impacted, as well as industry leaders like UnitedHealth Group, Humana, and CVS. UNH, with a $291 billion market cap, provides coverage to over 150 million worldwide.

UnitedHealth Group’s stock has fluctuated between $234.60 and $622.83 in the past 52 weeks, down over 30% in 2025. With a P/E ratio of 15.43x and a market cap of $291 billion, UNH is considered undervalued compared to competitors like Elevance and Humana. The company’s strong ROE, profit margin, and dividend history make it a stable investment choice.

UNH reported Q3 earnings of $2.59 EPS, driven by growth in Optum and UnitedHealthcare. Revenue reached $113.2 billion, up 12% YoY. 2025 guidance includes revenue of $445.5 billion to $448.0 billion and EPS of $14.65 or $16.25. Analysts have a “Moderate Buy” rating with a mean price target of $387.73, suggesting a 14% upside potential.

Management expects 2026 to bring solid growth in earnings, driven by Medicare Advantage and Optum. Despite political uncertainty, the market sentiment on Wall Street towards UnitedHealth remains cautiously optimistic. Analysts see potential for the stock to grow, with a mean price target implying a 14% upside from current levels.

Read more at Yahoo Finance: As Trump Calls Insurers ‘BIG,’ ‘BAD,’ and ‘Money Sucking,’ How Should You Play UnitedHealth Stock?